Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | 'Pharma clinical trial services market will reach $30.6 billion in 2015' Predicts VisiongainA new report by Visiongain predicts that the world market for pharma clinical trial services will be worth $30.6bn in 2015. Between 2011 and 2017, the global market will grow with a high single digit CAGR.
By: Visiongain Throughout the 10-year forecast period, late-stage trials will account for the greatest proportion of revenues for clinical research organisations (CROs). In the first half of the forecast period, lifecycle management strategies, demands from regulators for post-marketing safety studies and pharma co economic data will drive growth in that industry. Richard Lang, a pharmaceutical industry analyst for visiongain, said: “In the last decade, demand for outsourced clinical trial services grew rapidly as pharma pipelines grew and trials became increasingly large and complex. Drug developers built up large, complex networks of service providers, which they are now seeking to simplify. They are looking to form strategic partnerships with a select few CROs covering long-term development projects. “CROs must expand to offer a one-stop shop for pharmaceutical clients in order to take advantage of these strategic partnerships. They will look to new technology, including e-clinical tools, to improve their service offerings, as well as expanding into emerging markets. Many leading CROs established bases in BRIC nations in the last decade. In this decade, growth for these CROs will be focused on building upon the service portfolio in these markets, as well as entering new emerging markets in Asia, Latin America and Central and Eastern Europe.” Opportunities for growth in this decade for small CROs will stem from specialisation. Demand for biomarker validation services offers one potential niche area in which all larger CROs have yet to invest heavily. Therapeutic specialisation offers another opportunity to these companies. Cancer, cardiovascular diseases and CNS disorders accounted for more than half of clinical trial service revenues in 2011. Strong growth is expected in all three sectors of the market in this decade, driven by rising disease incidence and unmet treatment needs. There were close to 1,000 cancer drugs in clinical development in 2012, with many more in pre-clinical development. The new study forecasts the leading national pharma clinical trials service markets. In 2011, the US and Western Europe dominated the market, accounting for more than three quarters of global revenues. During this decade, however, pharmaceutical clients will increasingly demand trial services in emerging countries. Lower costs and large treatment-naï Pharma Clinical Trial Services: World Market 2013-2023 provides quantitative and qualitative analysis of the clinical trial services market. It shows revenue forecasts for world-level submarkets and national markets. Also, it identifies future trends that will affect market players. The study adds to Visiongain’s portfolio of analytical reports covering the pharmaceutical outsourcing and service markets. For further information concerning the Visiongain’s Pharma Clinical Trial Services: World Market 2013-2023 report please visit: http://www.visiongain.com/ Contact: Email: Sara Peerun on sara.peerun@ Tel: +44 (0) 20 7336 6100 Companies Listed 3C Alliance Agência Nacional de Vigilância Sanitária (ANVISA) [Brazil] Agility Clinical Allscripts Amgen Aptuit ASAN Medical Center Associação Brasileira de CROs (Abracro) Association for the Accreditation of Human Research Protection Programs (AAHRPP) Association of Clinical Trial Organisations (ACTO) [Russia] Astellas Pharma Avista Capital Partners Bayer BeijingWits Medical Consulting (part of ICON) Berry Consultants BioClinica BioDuro (part of PPD) BioDuro Biologics BioTrak BML Boehringer Ingelheim Bristol-Myers Squibb Caprion Proteomics Catalent Center for Biologics Evaluation and Research (CBER) [US] CenterWatch Central Drugs Standard Control Organization (CDSCO) [India] Charles River Laboratories Chinese Ministry of Commerce Clinical Trial Support Clinigene International Clinipace Worldwide ClinStar CMIC CMIC (Beijing) Co CNS Healthcare CNS Vital Signs Cogtest (part of The Cognition Group) Corex Pharmaceutical Council for International Organizations of Medical Sciences (CIOMS) Cromos Pharma Czura Thornton Dako (part of Agilent Technologies) Department of Health [UK] Drug Controller General of India (DCGI) Eisai Ekam Imaging Eli Lilly European Commission European Federation of Pharmaceutical Industries and Associations (EFPIA) European Medicines Agency (EMA) European Parliament Firecrest Clinical (part of ICON) Food and Drug Administration (US FDA) GCP ClinPlus GE Healthcare Genstar Capital Global CNS Research Global Research Services (GRS) GSK Hellman & Friedman i3 Research (part of inVentiv Health) ICON INC Research Infociencia (part of RPS) Innovative Medicines Initiative (IMI) Inspire Institute for Medical Research Management and Biometrics (IMEREM, part of RPS) Integrium International Cancer Genome Consortium International Conference of Harmonisation (ICH) inVentiv Health J&J Japan Pharmaceutical Manufacturers Association (JPMA) Java Clinical Julphar Kendle (part of INC Research) Kforce Kforce Clinical Research (KCR, part of inVentiv Health) Kinship Technologies (part of PRA) Korea Drug Development Fund (KDDF) Korea Food and Drug Administration (KFDA) Korea National Enterprise for Clinical Trials (KoNECT) Kun Tuo (part of Quintiles) LSK Global MAB Discovery Malaysian Biotechnology Corporation Maximax Pharmaceutical Research MDS Pharma Services (part of INC Research) MedAvante Medelis Medicines and Healthcare products Regulatory Agency (MHRA) [UK] Medidata Solutions Medipal Holdings Medivation Merck & Co. Merck KGaA Metabolon MetricStream Ministry of Health, Labor and Welfare (MHLW, Japan) Molecular Neuroimaging Myriad Genetics National Cancer Institute (NCI) [US] National Taiwan University Hospital (NTUH) Nautic Partners Neuroimage NextGen Sciences Nexus Oncology NHS Research Scotland (NRS) OCT Omnicare Ontario Teachers' Pension Plan Oxford Cancer Biomarkers Oxford Gene Technology (OGT) Oxford Outcomes (part of ICON) Pacific Biomarkers Paragon Biomedical (part of Clinipace Worldwide) Paramax International (part of RPS) Parexel International Perceptive Informatics (part of Parexel) PFC Pharma Focus (part of Clinipace Worldwide) Pfizer Pharmaceutical Research and Manufacturers of America (PhRMA) Pharmaceuticals and Medical Devices Agency (PMDA) [Japan] PharmaNet Development Group (part of inVentiv Health) PPD PRA International Prana Biotechnology PriceSpective (part of ICON) Prodia Clinical Laboratory Proteome Sciences ProTrials Research Psychmed (part of The Cognition Group) QED Clinical Services Quintiles Regulus Pharmaceutical Consulting (part of Clinipace Worldwide) ReSearch Pharmaceutical Services (RPS) Rules Based Medicine (now Myriad RBM, part of Myriad Genetics) Samsung ... End
Account Phone Number Disclaimer Report Abuse
|
|